临床医学工程
臨床醫學工程
림상의학공정
CLINICAL MEDICAL ENGINEERING
2014年
10期
1281-1282
,共2页
重组人脑利纳肽%急性心力衰竭%疗效分析
重組人腦利納肽%急性心力衰竭%療效分析
중조인뇌리납태%급성심력쇠갈%료효분석
Recombinant human brain natriuretic peptide%Acute heart failure%Curative effect analysis
目的:研究观察重组人脑利钠肽(rhBNP)治疗急性心力衰竭的疗效。方法选取2011年12月至2013年3月期间我院收治的185例急性心力衰竭的患者,将其随机分为实验组(95例)与对照组(90例)。所有患者均依据急性心力衰竭诊断和治疗指南进行诊断和治疗,其中实验组在对照组的基础上加用重组人脑利钠肽进行治疗,比较两组患者治疗时间和治疗效果等指标。结果实验组患者住院时间少于对照组,而治疗效果优于对照组,差异具有统计学意义(P<0.05)。结论重组人脑利钠肽的应用可以有效提高急性心力衰竭的治疗效果,减少治疗时间,应大力推广使用。
目的:研究觀察重組人腦利鈉肽(rhBNP)治療急性心力衰竭的療效。方法選取2011年12月至2013年3月期間我院收治的185例急性心力衰竭的患者,將其隨機分為實驗組(95例)與對照組(90例)。所有患者均依據急性心力衰竭診斷和治療指南進行診斷和治療,其中實驗組在對照組的基礎上加用重組人腦利鈉肽進行治療,比較兩組患者治療時間和治療效果等指標。結果實驗組患者住院時間少于對照組,而治療效果優于對照組,差異具有統計學意義(P<0.05)。結論重組人腦利鈉肽的應用可以有效提高急性心力衰竭的治療效果,減少治療時間,應大力推廣使用。
목적:연구관찰중조인뇌리납태(rhBNP)치료급성심력쇠갈적료효。방법선취2011년12월지2013년3월기간아원수치적185례급성심력쇠갈적환자,장기수궤분위실험조(95례)여대조조(90례)。소유환자균의거급성심력쇠갈진단화치료지남진행진단화치료,기중실험조재대조조적기출상가용중조인뇌리납태진행치료,비교량조환자치료시간화치료효과등지표。결과실험조환자주원시간소우대조조,이치료효과우우대조조,차이구유통계학의의(P<0.05)。결론중조인뇌리납태적응용가이유효제고급성심력쇠갈적치료효과,감소치료시간,응대력추엄사용。
Objective To study the effect of recombinant human brain natriuretic peptide (rhBNP) in the treatment of patients with acute heart failure. Methods 185 cases of patients with acute heart failure treated in our hospital from December 2011 to March 2013 were retrospectively analysed and randomly divided into experimental group (95 cases) and control group (90 cases). All the patients were dignosed and treated according to the guide of the dignosis and treatment of acute heart failure, the experimental group received recombinant human brain natriuretic peptide on the basis of control group, the time and treatment effect of the two groups was compared. Results The hospitalization time of the experimental group was shorter than that of the control group, and the treatment effect of the experimental group was better than those of the control group, with statistical significant difference (P <0.05). Conclusions The application of recombinant human brain natriuretic peptide can effectively improve the treatment effect of acute heart failure and reduce the treatment time, which is wrothy of application and promotion.